Novozymes has underestimated fluctuating bioenergy industry
![](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article11023119.ece/ALTERNATES/schema-16_9/Prisca_ExLT_5760x3840.jpg)
On Monday, Novozymes Chief Executive Peder Holk Nielsen and Chief Financial Officer Prisca Havranek-Kosicek present the company's strategy for the next three years.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novozymes downgrades following failing sales
For subscribers
Novozymes' US growth outlook dwindles
For subscribers
Novozymes CFO: Powerful momentum in bioenergy division
For subscribers